Last update 29 Aug 2025

Ombitasvir/Paritaprevir/Ritonavir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ABT-267/ABT-450/ritonavir, ABT-267/ritonavir/ABT-450, ABT-450/ABT-267/ritonavir
+ [12]
Action
inhibitors
Mechanism
HIV-1 pol inhibitors(Human immunodeficiency virus type 1 Pol protein inhibitors), NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), NS5A inhibitors(Nonstructural protein 5A inhibitors)
Originator Organization
Active Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (14 Jan 2015),
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Special Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC37H48N6O5S2
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N
CAS Registry155213-67-5
View All Structures (3)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic hepatitis C genotype 1
China
20 Sep 2017
Hepatitis C
United States
24 Jul 2015
Hepatitis C, Chronic
European Union
14 Jan 2015
Hepatitis C, Chronic
Iceland
14 Jan 2015
Hepatitis C, Chronic
Liechtenstein
14 Jan 2015
Hepatitis C, Chronic
Norway
14 Jan 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 3
Australia
01 Jun 2016
HIV InfectionsPhase 3
New Zealand
01 Jun 2016
HIV InfectionsPhase 3
United Kingdom
01 Jun 2016
Hepatocellular CarcinomaPhase 3-01 Jul 2015
Decompensated cirrhosis of liverPhase 3-24 Nov 2014
Kidney Failure, ChronicPhase 3-23 Sep 2014
Chronic hepatitis C genotype 2Phase 3-01 Jan 2014
Compensated cirrhosisPhase 3-01 Oct 2012
FibrosisPhase 3-01 Oct 2012
Chronic hepatitis C genotype 1bPhase 3-01 Aug 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
200
vwwmiuwnnu = nockdueidb oulcfrevyr (ztibcftibh, myfptsqzub - ogqtjinlen)
-
22 Jan 2021
vwwmiuwnnu = gdhpylgsez oulcfrevyr (ztibcftibh, mewoydfxav - lzdscenxmd)
Not Applicable
Hepatocellular Carcinoma
Alfa feto protein
165
Ombitasvir/Paritaprevir/Ritonavir (OMV/PTV/RTV) regimen
qwurwhnbyo(xhepomciuj) = vrveoerwev aobyzhpcgb (eiamqjrskn )
Positive
06 Jun 2020
qwurwhnbyo(xhepomciuj) = ionouhrxvy aobyzhpcgb (eiamqjrskn )
Phase 4
46
hqazgvqwbo = dlfrgfxelw kkioehusuv (piahxavsji, aoydpbahxz - rapvomycsh)
-
19 Jul 2019
Phase 2
46
(Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks])
nuylfxguve = bxuamemvsf wzitofnhqm (axfilqsanl, jehqsrotpa - gxmmkglgqy)
-
04 Jun 2019
(Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks])
nuylfxguve = qegiluvzul wzitofnhqm (axfilqsanl, qomftziwby - magbxzzjui)
Phase 3
2,211
wjmzehccfs(aeishygqir) = srslbibgfa czmwxbvgxw (wfwrhttnce )
-
13 Apr 2019
Phase 1
110
gtaucqksky(euwccbydtt) = There were no reported serious adverse events ovcqxqzqmf (azyufpcnoc )
-
01 Feb 2019
Phase 3
104
cicquiowcc = tvnrnwuxxv lqfhckmrxw (rwyoayxkpy, tkciwtnndg - zktlyvdkki)
-
09 Oct 2018
Phase 2
70
(Arm A (Genotype [GT]3, Noncirrhotic))
nzqpuglnmw = zzuytefzcz aamphccdmt (hbbinruzua, afpdbedoja - taxujogunt)
-
06 Jul 2018
(Arm B (GT3, Noncirrhotic))
nzqpuglnmw = pqitlxamqz aamphccdmt (hbbinruzua, hxskbbibbq - mmuawjaqjg)
Phase 3
166
zjiwarhmqt = vgepqnxufb vcywqyrhfj (qofmsyfmnm, jqbtjqkicn - kryqcafzzx)
-
13 Dec 2017
Phase 3
3
jbxecuroem(tbhadwcqbs) = zyeswnadgu xxfxqqearq (gfgfrbrfgk, fhkalgtirr - rvbahgsncb)
-
12 Dec 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free